Pharvaris N.V. (NASDAQ:PHVS) Stock Has Consensus Price Target of $59.87 According to Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $59.87.

PHVS has been the subject of a number of research reports. Rosenblatt Securities set a $60.00 target price on Pharvaris in a report on Wednesday, September 9th. Oppenheimer restated an “outperform” rating and issued a $75.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, September 8th. Morgan Stanley lifted their price target on shares of Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. Finally, Guggenheim boosted their price objective on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th.

Insider Buying and Selling

In other news, Director Johannes Gerardus Chri Schikan sold 800 shares of Pharvaris stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $36.19, for a total transaction of $28,952.00. Following the sale, the director owned 115,167 shares in the company, valued at $4,167,893.73. This trade represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Viviane Monges sold 11,969 shares of the business’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $33.05, for a total transaction of $395,575.45. Following the transaction, the director directly owned 5,500 shares in the company, valued at approximately $181,775. The trade was a 68.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 513,102 shares of company stock valued at $18,643,666 over the last three months. Company insiders own 11.84% of the company’s stock.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in PHVS. venBio Partners LLC acquired a new stake in shares of Pharvaris during the second quarter valued at about $160,569,809. Wellington Management Group LLP lifted its stake in shares of Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after acquiring an additional 274,034 shares in the last quarter. Commodore Capital LP lifted its stake in shares of Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after acquiring an additional 29,525 shares in the last quarter. 5AM Venture Management LLC purchased a new position in Pharvaris in the second quarter valued at about $27,581,008. Finally, Seven Fleet Capital Management LP grew its stake in Pharvaris by 144.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after purchasing an additional 457,804 shares in the last quarter.

Pharvaris Trading Down 2.2%

Shares of Pharvaris stock opened at $31.01 on Tuesday. Pharvaris has a twelve month low of $20.65 and a twelve month high of $43.25. The stock has a market capitalization of $2.03 billion, a P/E ratio of -10.17 and a beta of -2.46. The business’s fifty day moving average price is $35.11 and its 200 day moving average price is $32.17.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris will post -3.12 EPS for the current year.

Pharvaris Company Profile

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.